香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司第八屆董事會第二十一次會議決議公告》、《上海醫藥集 團股份有限公司關於高級管理人員變動的公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 4 月 9 日 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 1、《关于聘任公司高级管理人员的议案》 同意聘任周亚栋女士担任公司副总裁兼财务总监，任期至第八届董事会届满 时止。同时沈波先生不再担任公司财务总监职务。 证券代码：6016 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 证券代码：601607 证券简称：上海医药 公告编号：临2025-044 上海医药集团股份有限公司 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於入選全球最具價值醫藥品牌 25 強的自願性公告》 僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 4 月 8 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非 ...

Market News - The National Bureau of Statistics will release March CPI and PPI data on April 10, with February figures showing a month-on-month CPI decrease of 0.2% and a year-on-year decrease of 0.7%, while PPI decreased by 0.1% month-on-month and 2.2% year-on-year [2] - The People's Bank of China has 763.4 billion yuan in reverse repos and 150 billion yuan in treasury cash deposits maturing this week, with specific amounts maturing each day [3] - The U.S. will release March CPI data on April 10, which is expected to be a significant test for the dollar, as persistent inflation could support the dollar and raise concerns about further interest rate cuts by the Federal Reserve [4] Sector Events - The 10th China Science and Technology Finance Forum will be held in Beijing on April 7, focusing on summarizing reform achievements and innovative paths for the future of technology finance [6] - The 2025 Global 6G Technology and Industry Ecosystem Conference will take place in Nanjing from April 10 to 12, gathering global leaders in the 6G field to discuss innovation and future industry development [7] - The Ministry of Commerce has announced export controls on seven categories of medium and heavy rare earths, effective immediately, to safeguard national security and fulfill international obligations [8] - Amazon plans to launch its first batch of 27 satellites for its Project Kuiper on April 9, entering competition with SpaceX's Starlink [9] Company News - HeXin Instruments plans to acquire a 56% stake in Shanghai Liangxi Technology Co., Ltd. through a combination of share issuance and cash payment [11] - Shengnong Development intends to acquire a 54% stake in Anhui Sun Valley Food Technology Group for 1.126 billion yuan, enhancing its integrated industry chain [12] - Lier Chemical expects a net profit of 145 to 155 million yuan for Q1 2025, representing a year-on-year increase of 203.08% to 223.98% due to rising sales and prices [13] - Stone Technology reported a revenue of 11.945 billion yuan for 2024, a year-on-year increase of 38.03%, and a net profit of 1.977 billion yuan, a decrease of 3.64% [14] - Chengdi Xiangjiang announced a contract worth 4.452 billion yuan for a data center project with China Mobile, with a cooperation period of seven years plus an uncertain duration [15] Restricted Shares - This week, 24 companies in the A-share market will have a total of 1.735 billion shares released from restrictions, with a total market value of 35.015 billion yuan, an increase of 12.411 billion yuan week-on-week [17] New Stock Calendar - Two new stocks are set to be issued this week, with a total of approximately 42.6 million shares and expected fundraising of 1.161 billion yuan [21] Market Outlook - Dongfang Securities suggests the market may see a turning point post-holiday, with potential for a rebound as policy benefits are released in Q2 [24] - Founder Securities believes A-shares may perform better than global markets due to positive macro policies and recovering domestic demand [25] - Dongguan Securities anticipates a range-bound market in the short term due to global volatility and upcoming earnings reports [26] - Guojin Securities recommends a shift in investment strategy towards large-cap value stocks, focusing on "profit bottom" logic in the upcoming quarter [27]

Core Viewpoint - The China Securities Index for the medical industry has shown a slight decline over the past month, quarter, and year-to-date, indicating a stable but slightly negative trend in the sector [2]. Group 1: Index Performance - The China Securities Index for the medical industry is currently at 566.67 points [1]. - Over the past month, the index has decreased by 0.49%, while it has seen a minimal decline of 0.02% over the past three months and year-to-date [2]. Group 2: Index Composition - The top ten weighted companies in the index include: - Mindray Medical (14.12%) - Aier Eye Hospital (8.91%) - United Imaging Healthcare (7.39%) - Aimeike (3.93%) - Huatai Medical (3.48%) - New Industries (3.41%) - Yuyue Medical (3.12%) - Shanghai Pharmaceuticals (3.04%) - Meinian Onehealth (2.57%) - Jiuan Medical (2.39%) [2]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (57.38%) and the Shanghai Stock Exchange (42.62%) [2]. Group 3: Sector Allocation - The sector allocation within the index is as follows: - Medical Devices: 34.29% - Medical Consumables: 23.16% - Pharmaceutical Commerce: 15.33% - Medical Services: 14.26% - In Vitro Diagnostics: 12.95% [2]. Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December [3]. - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to significant events affecting sample companies [3].

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 * 僅供識別 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於 2019 年 A 股股票期權激勵計畫預留股票期權第三 個行權期 2025 年第一季度自主行權結果公告》、《上海醫藥集團股份有限公司關於向特定對 象發行限售股上市流通的公告》、《國投證券股份有限公司關於上海醫藥集團股份有限公司向 特定對象發行限售股上市流通的核查意見》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站 (http://www.sse.com.cn)刊登的《上海醫藥集團股份有限公司關於高級管理人員離 任的公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 4 月 1 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 证券代码：601607 证券简称：上海医药 公告编号 ...

EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 上海醫藥集團股份有限公司 | | 股份代號 | 02607 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度之末期股息 | | 公告日期 | 2025年3月28日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 10 股 2.9 RMB | | 股東批准日期 | 有待公佈 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 有待公佈 | | 匯率 | 有待公佈 | | ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站 (http://www.sse.com.cn)刊登的《上海醫藥集團股份有限公司第八屆董事會第二十 次會議決議公告》、《上海醫藥集團股份有限公司第八屆監事會第十一次會議決議 公告》、《上海醫藥集團股份有限公司 2025 年度日常關聯交易公告》、《上海醫藥 集團股份有限公司關於註銷公司 2019 年 A 股股票期權激勵計畫首次授予股票期 權第三個行權期及預留股票期權第二個行權期已到期未行權的股票期權的公告》、 《國浩律師（上海）事務所關於上海醫藥登出 ...

Financial Performance - Shanghai Pharmaceuticals reported its annual performance for the year ending December 31, 2024, in accordance with Chinese accounting standards[3]. - Revenue for 2023 reached RMB 260.30 billion, a 12.2% increase from RMB 231.98 billion in 2022[20]. - Pre-tax profit for 2023 was RMB 7.05 billion, a decrease of 20% compared to RMB 8.81 billion in 2022[20]. - The company achieved a net profit of RMB 5.17 billion in 2023, down from RMB 6.99 billion in 2022, reflecting a decline of 26.2%[20]. - In 2024, the company achieved a total revenue of RMB 275.251 billion, representing a year-on-year growth of 5.75%[28]. - The net profit attributable to shareholders reached RMB 4.553 billion, an increase of 20.82% year-on-year[29]. - The pharmaceutical industrial segment reported a sales revenue of RMB 23.731 billion, a decline of 9.62% year-on-year, while the pharmaceutical commercial segment achieved RMB 251.520 billion, a growth of 7.47%[28]. - The company reported a net operating cash flow of RMB 5.827 billion, up 11.39% year-on-year, indicating sustained high-quality development[31]. - The company's operating revenue for the current period reached ¥275.25 billion, an increase of 5.75% compared to ¥260.30 billion in the same period last year[58]. - Operating costs increased by 6.84% to ¥244.62 billion from ¥228.97 billion, driven by the rise in sales revenue[58]. Research and Development - Research and development investment totaled RMB 2.818 billion, with R&D expenses of RMB 2.394 billion, reflecting an 8.64% increase year-on-year[30]. - The company has established a new product planning department to optimize its product pipeline, focusing on areas such as immunology, oncology, cardiovascular, digestive metabolism, and anti-infection diseases[36]. - The company is focusing on optimizing its product pipeline in biopharmaceuticals, chemical drugs, traditional Chinese medicine, and rare diseases[24]. - The company has 5 innovative drugs in clinical phase III and 32 projects in various clinical stages[37]. - The company is actively exploring multiple rare disease areas with its innovative antibody drugs, aiming to provide effective treatments for patients[40]. - The company is committed to continuous innovation and market expansion through strategic R&D efforts[74]. - The company has a diverse pipeline with drugs targeting various therapeutic areas, including cardiovascular, diabetes, and infectious diseases[76]. Strategic Initiatives - The company aims to become a respected leading brand in pharmaceutical manufacturing and health services[5]. - The company is advancing its digital transformation with the establishment of smart factories, including the first "Future Factory" in the Zhejiang pharmaceutical industry[24]. - The company is committed to building an innovative ecosystem through collaborations with top universities and research institutions[23]. - The establishment of the Shanghai Frontier innovation ecosystem has successfully attracted 15 partner organizations and innovation enterprises[34]. - Strategic collaborations in cell and gene therapy are progressing, with partnerships signed with several medical institutions to advance product innovation and industrialization[35]. - The company is actively expanding into international markets and adjusting its strategies in response to healthcare cost control and payment reforms[90]. Corporate Governance - The board of directors has reviewed the annual performance report, ensuring its accuracy and completeness[3]. - The board of directors includes both executive and independent non-executive members, ensuring diverse governance[4]. - The company has confirmed the independence of its independent non-executive directors as per Hong Kong listing rules[103]. - The company has no significant contracts with controlling shareholders during the reporting period[107]. Market Position and Recognition - The company was ranked 411th in the Fortune Global 500 and recognized in multiple industry rankings, including the top 50 global pharmaceutical companies[28]. - The company is positioned as one of the top 50 global pharmaceutical enterprises, transitioning from a generic drug company to a research-driven pharmaceutical enterprise[51]. Employee and Management - The company employed a total of 49,402 staff, with 19,370 in sales and 15,152 in production roles[173]. - The company has established a differentiated compensation system for various employee categories, effectively motivating all employees to enhance company performance[174]. - The total pre-tax compensation for executives during the reporting period amounted to CNY 1,796.17 million[185]. - The company has conducted 25 types of training projects with 141 sessions, completing over 100,000 training instances, and launched a digital learning platform with over 10,000 projects and 5,000 courses[178]. Financial Management - The company has increased investment in mergers and acquisitions, actively expanding international business, with a signed agreement to acquire 10% of the shares of Huanlong Pharmaceutical by December 2024[46]. - The company has registered 18 new overseas products this year, bringing the total to 25, with one product approved[46]. - The company has established internal compliance and risk management policies to ensure adherence to legal requirements[162]. - The company maintains strong relationships with stakeholders, including employees, customers, and suppliers, to achieve sustainable development[163]. Future Outlook - The company provided an optimistic outlook, projecting a revenue growth of 20% for the next quarter, targeting $1.44 billion[3]. - The company aims to enhance its core competitiveness and contribute to the "Healthy China 2030" initiative by improving its multi-level pharmaceutical distribution network and digital supply chain capabilities[87]. - By 2025, the company plans to strengthen its industrial foundation and enhance the value contribution of its traditional Chinese medicine, micro-ecology, and health businesses, while focusing on the integration of research and development[89].

上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） (股份代碼: 02607) 董事名單及其角色和職能 於 2025 年 3 月 27 日，上海醫藥集團股份有限公司董事會(「董事會」)成員列示如下： 執行董事: 楊秋華先生（董事長） 沈波先生 李永忠先生 董明先生 非執行董事: 張文學先生 獨立非執行董事: 顧朝陽先生 霍文遜先生 王忠先生 萬鈞女士 戰略委員會: 楊秋華先生（召集人） 張文學先生 王忠先生 提名委員會: 霍文遜先生（召集人） 沈波先生 顧朝陽先生 萬鈞女士 審計委員會: 顧朝陽先生（召集人） 霍文遜先生 王忠先生 薪酬與考核委員會: 王忠先生（召集人） 楊秋華先生 顧朝陽先生 中國上海，2025 年 3 月 27 日 * 僅供識別 ...